Please try another search
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. Its core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; IMM2902 that in Phase I clinical trial for the treatment of HER2-positive and low expressing solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors. The company was incorporated in 2015 and is headquartered in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Yu Xiaoyong | 52 | 2015 | Non-Executive Director |
Li Song | 39 | 2015 | VP of R&D and Executive Director |
Kendall Arthur Smith | 82 | 2022 | Independent Non-Executive Director |
Zhenping Zhu | 59 | 2016 | Independent Non-Executive Director |
Zimeng Zhao | 33 | 2022 | Employee Representative Supervisor |
Cong Xu | 38 | 2020 | Non-Executive Director |
Yeung Chi Tat | 54 | 2022 | Independent Non-Executive Director |
Miao Tian | 32 | 2017 | Supervisor |
Yu Zhihua | 57 | 2018 | Non-Executive Director |
Jiefeng Gu | 41 | 2016 | Chairman of the Supervisory Committee |
Guan Mei | 41 | 2022 | Secretary, Director of the Financing and Investment Strategy Department & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review